3C
DRNA

361 Capital’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

361 Capital’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$1.11M Sell
43,821
-6,826
-13% -$147K 0.52% 18
2020
Q1 		$930K Buy
+50,647
New +$984K 0.42% 60

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

361 Capital's DRNA Position: Q2 2020 in Review

361 Capital reduced its Dicerna Pharmaceuticals, Inc. (DRNA) stake by 13% in Q2 2020, selling an estimated $147K and leaving 43,821 shares worth $1.11M. The position accounts for 0.52% of the portfolio, ranked #18.

361 Capital first reported a position in DRNA in Q1 2020 and has held it in 2 quarters since. 170 funds tracked by Wall St. Rank hold DRNA as of Q2 2020.

  • 361 Capital held 43,821 shares of Dicerna Pharmaceuticals, Inc. worth $1.11M as of Q2 2020.
  • 361 Capital sold 6,826 Dicerna Pharmaceuticals, Inc. shares in Q2 2020, an estimated $147K.
  • Dicerna Pharmaceuticals, Inc. made up 0.52% of 361 Capital's portfolio in Q2 2020, its #18 holding.
  • 361 Capital first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2020 and has held it in 2 quarters since.
  • 170 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.